Discussion on the effect of osimertinib and its infectivity in patients without mutations

Osimertinib is a targeted therapy for EGFR mutated non-small cell lung cancer (NSCLC), and its clinical efficacy has been widely recognized.

As far as the effect of osimertinib in patients without mutations is concerned, based on existing clinical research and understanding of the drug mechanism, the use of osimertinib in such patients may not achieve the expected therapeutic effect. The main mechanism of action of osimertinib is to specifically inhibit the activity of mutated EGFR protein, thereby blocking the growth signaling pathway of cancer cells. For patients who do not have EGFR mutations, the drug cannot find its target, so it may be difficult to exert an effective anti-tumor effect.

More importantly, blind use of osimertinib may also lead to a series of adverse reactions and the development of drug resistance. This will not only delay the patient's treatment time, but may also accelerate the progression of the disease. Therefore, for patients without mutations, it is not recommended to use osimertinib blindly, but other suitable treatment options should be selected under the guidance of a doctor.

As for the infectivity of osimertinib, this was not addressed in the current study. As an anti-tumor drug, osimertinib's main target is cancer cells in the patient's body, not pathogens or viruses. Therefore, from the perspective of drug mechanism, osimertinib is not infectious. During the use of osimertinib, patients and medical staff need to pay attention to the correct use of the drug and possible adverse reactions, rather than worrying about its infectivity.

In general, the effect of using osimertinib in patients without mutations may not be ideal, and may even bring about a series of adverse consequences. Therefore, when choosing a treatment plan, patients should fully understand their condition and the indications of the drugs, and follow the doctor's recommendations for standardized treatment. At the same time, regarding the contagiousness issue of osimertinib, patients and medical staff can rest assured that the drug is not contagious. During the treatment process, maintaining good living habits and a positive attitude are equally important to improving treatment effects and promoting recovery.